Seeking male and female participants under the age of 25, who were diagnosed with Chronic Myeloid Leukemia before the age of 18, to determine if they can stop taking their TKI medication and remain in remission as well as if restarting TKI will re-achieve remission.
Seeking people aged 2-21 years who have been diagnosed with Philadelphia chromosome positive (Ph+) or ABL-class fusion positive Acute Lymphoblastic Leukemia (ALL) for a study of whether using a less toxic chemotherapy in combination with a drug called imatinib can keep the cancer from returning after treatment.
Seeking children and young adults 31 years old or younger who have been newly diagnosed with standard risk B-cell Acute Lymphoblastic Leukemia (B-ALL), Down syndrome B ALL or localized B-cell Lymphoblastic Lymphoma (B-LLy) for a study of chemotherapy.
Children and young adults up to age 25 with High-Risk B-cell acute lymphoblastic leukemia (B-ALL) sought for a study of an investigational drug in combination of chemotherapy based on individual disease characteristics to improve 5-year disease-free survival (DFS).
Seeking children and young adults whose CD22+ B-Acute Lymphoblastic Leukemia (B ALL) has come back (relapsed) after treatment or has not responded (refractory) for a study of an investigational drug. While the investigational drug has been approved for use adults with leukemia, it has not yet been approved for use in children.
Seeking adults with Acute Myeloid Leukemia with an NPM1 mutation or KMT2A rearrangement for a study of an investigational drug to be used in combination with other chemotherapy drugs.
Seeking adults whose Multiple Myeloma has returned after treatment (Relapsed or Refractory) for a study of an investigational drug combination.
Seeking men and women who have a type of cancer that affects the B-cells (a type of white blood cells) in your blood that has not responded to, or who could not tolerate, the standard treatments normally given for this type of cancer for a study of an investigational drug.
Seeking men and women aged 18-65 years whose large B-Cell lymphoma has not responded or come back after treatment for a study of an investigational drug combination.
Seeking men and women who have had stem cell transplant or cellular therapy for their blood cancer for a study of a COVID-19 vaccine.